HomeCompareGNNSF vs GBDC

GNNSF vs GBDC: Dividend Comparison 2026

GNNSF yields 140.85% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $2.62M in total portfolio value· pulled ahead in Year 10
10 years
GNNSF
GNNSF
● Live price
140.85%
Share price
$1.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.23M
Annual income
$7,605,007.88
Full GNNSF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — GNNSF vs GBDC

📍 GBDC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNNSFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNNSF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNNSF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNNSF
Annual income on $10K today (after 15% tax)
$11,971.83/yr
After 10yr DRIP, annual income (after tax)
$6,464,256.70/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $7,518,867.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNNSF + GBDC for your $10,000?

GNNSF: 50%GBDC: 50%
100% GBDC50/50100% GNNSF
Portfolio after 10yr
$19.54M
Annual income
$12,027,870.86/yr
Blended yield
61.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

GNNSF
No analyst data
Altman Z
2.7
Piotroski
5/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNNSF buys
0
GBDC buys
0
No recent congressional trades found for GNNSF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNNSFGBDC
Forward yield140.85%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$18.23M$20.85M
Annual income after 10y$7,605,007.88$16,450,733.83
Total dividends collected$16.79M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: GNNSF vs GBDC ($10,000, DRIP)

YearGNNSF PortfolioGNNSF Income/yrGBDC PortfolioGBDC Income/yrGap
1$24,785$14,084.51$12,492$1,791.70+$12.3KGNNSF
2$59,143$32,624.07$16,527$3,160.58+$42.6KGNNSF
3$136,042$72,758.05$23,588$5,904.90+$112.5KGNNSF
4$301,974$156,409.10$37,141$11,901.65+$264.8KGNNSF
5$647,582$324,470.73$66,205$26,463.38+$581.4KGNNSF
6$1,343,219$650,306.15$137,452$66,612.65+$1.21MGNNSF
7$2,697,870$1,260,625.08$342,372$195,298.53+$2.36MGNNSF
8$5,253,056$2,366,334.87$1,053,292$686,954.33+$4.20MGNNSF
9$9,926,863$4,306,093.23$4,111,439$2,984,416.95+$5.82MGNNSF
10← crossover$18,226,751$7,605,007.88$20,849,974$16,450,733.83$2.62MGBDC

GNNSF vs GBDC: Complete Analysis 2026

GNNSFStock

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Full GNNSF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this GNNSF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNNSF vs SCHDGNNSF vs JEPIGNNSF vs OGNNSF vs KOGNNSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.